Earnings Call Summary | Compugen(CGEN.US) Q2 2024 Earnings Conference
Earnings Call Summary | Compugen(CGEN.US) Q2 2024 Earnings Conference
Net loss of $2.1 million or $0.02 per basic and diluted share in Q2 2024, improved from a net loss of $9.3 million or $0.11 per basic and diluted share in Q2 2023.The following is a summary of the Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript:
以下是Compugen醫療公司（CGEN）2024年第二季度業績會成績摘要：
Financial Performance:
金融業績：
Compugen reported Q2 2024 revenue of $6.7 million, a significant improvement compared to no revenue in Q2 2023.
Cash position as of June 30, 2024, stood at approximately $92.3 million, up from $51.1 million as of December 31, 2023.
Net loss of $2.1 million or $0.02 per basic and diluted share in Q2 2024, improved from a net loss of $9.3 million or $0.11 per basic and diluted share in Q2 2023.
Compugen醫療公司報告2024年第二季度營業收入爲670萬美元，相較於2023年第二季度無營收的情況有了顯著提升。
截至2024年6月30日，現金餘額約爲9230萬美元，相較於2023年12月31日的5110萬美元有所增長。
2024年第二季度淨虧損210萬美元，基本和稀釋後每股虧損0.02美元，相較於2023年第二季度淨虧損930萬美元或每股基本和稀釋後虧損0.11美元有了改善。
Business Progress:
業務進展：
FDA clearance for Phase I trial of COM503; initiation planned for Q4 2024 in solid tumors.
AstraZeneca advances development of rilvegostomig, a PD-1 TIGIT bispecific drug derived from COM902.
On track to report data from the COM701, COM902, and pembrolizumab triple combination study in platinum-resistant ovarian cancer patients in Q4 2024.
COM503獲得FDA覈准進行I期試驗；計劃在2024年第四季度在實體瘤患者中啓動。
阿斯利康推進rilvegostomig藥物的研發，這是一種從COM902中衍生出的PD-1 TIGIt雙特異性藥物。
按計劃，將於2024年第四季度報告來自於鉑金耐藥性卵巢癌患者的COM701、COM902和Pembrolizumab三聯療法研究數據。
Opportunities:
機會：
Significant potential revenue opportunity for Compugen arises from AstraZeneca's development of rilvegostomig with a target of over $5 billion in peak revenue.
The nonresponsive tumor types and patient populations for PD-1 may benefit from the triple combination strategy of blocking PVRIG, TIGIT, and PD-1.
阿斯利康研發rilvegostomig將爲Compugen醫療公司帶來一個重大的潛在收入機會，目標是超過50億美元的峯值營業收入。
PD-1非敏感腫瘤類型和患者人群可能受益於阻斷PVRIG、TIGIt和PD-1的三重療法策略。
More details: Compugen IR
更多詳情：Compugen醫療公司IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
